跳至主要内容
临床试验/KCT0007039
KCT0007039招募中未知

The Efficacy of Kami Guibi-tang for Improving Cognitive Function in Mild Cognitive Impairment Patients : A Randomized, Double-blind, Placebo-controlled Trial

Kyung Hee University Oriental Medicine Hospital at Gangdong0 个研究点目标入组 84 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
84

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
55?(Year) 至 90?(Year)(—)
性别
All

入选标准

  • 1. Those aged 55-90 who were diagnosed with amnestic mild cognitive impairment (aMCI) by a neurologist through the Seoul Neuropsychologic Screening Battery(SNSB) based on the diagnostic criteria for MCI suggested bt Albert et al.
  • - GDS(Global Deterioration Scale) = 3
  • - CDR (Clinical Dementia Rating) = 0.5
  • 2. Those who have not received cognitive-related medication within the last 2 weeks
  • - cognitive-related medication : Cerebral blood flow improvement agents such as gliatirin and tanamine, and other brain nutrients, which may affect brain cognition.
  • - Also excludes taking dementia treatments such as donepezil, rivastigmine, and gallantamine.
  • 3. Those who have been stable for the past 2 weeks or more without any change in the drug used for the underlying disease, and who are planned to be stable during this clinical trial.
  • 4. Those who have no problem with communication
  • 5. Those who do not qualify for disqualification related to MRI(magnetic resonance imaging).

排除标准

  • 1. Those who diagnosed with dementia by NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association)
  • 2. Those who diagnosed as vascular cognitive impairment by NINDS-AIREN
  • 3. Those with brain disorders that cause other neurological symptoms other than cognitive dysfunction
  • 4. Patients with degenerative brain disease such as Parkinson's disease, Huntington's chorea, Down syndrome, and Creutzfeldt-Jakob disease on history and neurological examination
  • 5. Cerebral trauma due to hypoxia such as cerebral trauma and carbon monoxide poisoning, vitamin deficiency, infectious diseases such as neurosyphilis or encephalitis, brain tumor, endocrine metabolic disease, mental retardation
  • 6. If there is evidence of clinically evident cerebrovascular disease, or if there is suspicion of a territorial infarct of cerebral blood vessels due to multiple strokes on MRI(magnetic resonance imaging)
  • 7. Patients with a history of convulsive disease (except for febrile convulsions in childhood)
  • 8. Those with a history of depression or who are currently suffering from depression
  • 9. Those with mental illness or who have behavioral problems requiring psychotropic medication
  • 10. Those who have substance abuse (drug addiction, alcoholism, etc.).
  • 11. Persons with physical disabilities that cause life threatening and require immediate treatment.
  • 12. Patients with uncontrolled hypertension
  • 13. Patients with Heart or kidney disease
  • 14. Patients with edema
  • 15. Those with gastrointestinal symptoms (anorexia, stomach discomfort, nausea, abdominal pain, diarrhea, etc.)
  • 16. Those who are taking medications that may cause hypokalemia or myopathy.
  • 17. Persons with hypersensitivity to the components of clinical trial medicines
  • 18. Those with possible pregnancy
  • 19. Patients with clinically significant abnormalities in blood chemistry (SGPT/ SGOT : more than 2 times the normal upper limit, serum creatinine: 10% of the normal upper limit)
  • 20. Those who participated in other clinical trials within 4 weeks(or Longer than 5 times the half-life of clinical trial drugs).
  • 21. An illiterate participant
  • 22. Other patients who were deemed inadequate by the tester

研究者

发起方
Kyung Hee University Oriental Medicine Hospital at Gangdong

相似试验